Neuroleptic malignant syndrome in Malaysia: a university hospital experience.
The neuroleptic malignant syndrome (NMS) is a potentially fatal complication of antipsychotic therapy. A retrospective study of nine patients seen over six years at the University Hospital, Kuala Lumpur (UHKL), is described. The estimated annualised incidence was 1.2 per 1000 in-patients with psychosis. No ethnic difference was detected. Clinical features were similar to experiences elsewhere, with wide variability seen in the severity of illness. The neuroleptic drugs implicated were haloperidol, trifluoperazine, chlorpromazine, fluphenazine and clopenthixol. Treatment consisted of withdrawal of offending drugs and supportive measures. Specific therapy was given to five patients. There was one death. At follow-up no deterioration was detected. A different neuroleptic drug was successfully re-introduced in four patients. In view of the wide usage of major tranquillizers, a high degree of clinical awareness of this serious complication is necessary for early diagnosis to reduce morbidity and mortality.
Department of Medicine, University of Malaya, Kuala Lumpur.
M K
MK
Lee
S B
SB
Ong
C T
CT
Tan
T G
TG
Loh
D000293:Adolescent; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects; D001971:Bromocriptine / Q000627:therapeutic use; D005260:Female; D006785:Hospitals, University; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis; D012189:Retrospective Studies
D014150:Antipsychotic Agents; D001971:Bromocriptine